Stockscreener 앱 받기
11.50
2.67%
-0.315
시간 외 거래:
11.50
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
New Forecasts: Here's What Analysts Think The Future Holds For Capricor Therapeutics, Inc. (NASDAQ:CAPR) - Simply Wall St
Check Out What Whales Are Doing With CAPR - Benzinga
High Growth Tech Stocks In The US Market With Promising Potential - Simply Wall St
(CAPR) Trading Signals - Stock Traders Daily
Capricor projects FDA priority review decision for deramiocel by August 2025 - MSN
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2024 Earnings Call Transcript - Insider Monkey
Capricor Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
Capricor Therapeutics Inc (CAPR) Q4 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
Capricor Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Is Capricor Therapeutics (CAPR) a Worst High-Risk High-Reward Growth Stock to Buy? - Insider Monkey
Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday - Benzinga India
Cantor Fitzgerald maintains $30 target on Capricor stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains $30 target on Capricor stock - Investing.com
A Glimpse Into The Expert Outlook On Capricor Therapeutics Through 4 Analysts - Benzinga
Capricor Therapeutics Stock (CAPR) Surges on Q4 Results and Promising New Therapy - The Globe and Mail
Capricor Therapeutics Reports 2024 Financial Results - TipRanks
Capricor: Q4 Earnings Snapshot - mySA
Earnings call transcript: Capricor Q4 2024 beats EPS forecast, stock up - Investing.com Canada
Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Capricor Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Capricor Therapeutics Inc Reports Q4 2024 Earnings: EPS Loss of - GuruFocus.com
Capricor Therapeutics Q4 Loss Widens, Revenue Decreases -March 19, 2025 at 04:39 pm EDT - Marketscreener.com
Capricor Therapeutics beats Q4 estimates, shares rise on FDA acceptance By Investing.com - Investing.com Canada
Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Capricor's DMD Breakthrough: FDA Fast-Tracks Novel Therapy as Cash Position Hits $151.5M - StockTitan
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely - Simply Wall St
While institutions own 38% of Capricor Therapeutics, Inc. (NASDAQ:CAPR), retail investors are its largest shareholders with 49% ownership - Yahoo Finance
Capricor Therapeutics announces long-term data from HOPE-2 OLE study - Yahoo Finance
H.C. Wainwright maintains Capricor stock Buy rating and $77 target By Investing.com - Investing.com UK
Capricor Therapeutics’ (CAPR) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
CAPRICOR THERAPEUTICS Earnings Preview: Recent $CAPR Insider Trading, Hedge Fund Activity, and More - Nasdaq
Capricor Therapeutics Announces Positive Data Demonstrating - GlobeNewswire
Capricor reports promising DMD treatment results - Investing.com
Capricor Therapeutics Says 3-Year Data Show Deramiocel Slows Duchenne Muscular Dystrophy - Marketscreener.com
Capricor reports promising DMD treatment results By Investing.com - Investing.com Australia
Capricor Therapeutics Reports 52% Slowing of Duchenne Muscular Dystrophy Disease Progression with Deramiocel in 3-Year Study Presentation at MDA Conference - Nasdaq
Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy - Yahoo Finance UK
Breakthrough: New DMD Drug Cuts Disease Progression in Half Over 3 Years - StockTitan
When the Price of (CAPR) Talks, People Listen - Stock Traders Daily
Capricor touts long-term efficacy of DMD therapy ahead of FDA application - MSN
Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) Price Target at $34.50 - Defense World
Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) PT at $34.50 - Armenian Reporter
Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition - AOL
Capricor at Leerink’s Conference: Strategic Moves in Cell Therapy By Investing.com - Investing.com UK
Rare Disease Biotech Capricor Therapeutics Announces Critical Year-End Earnings Date - StockTitan
Capricor Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 19, 2025 - Nasdaq
Capricor Therapeutics to Present Fourth Quarter and Full - GlobeNewswire
Capricor Therapeutics receives FDA acceptance of BLA for deramiocel - TipRanks
Capricor Therapeutics' Biologics License Application for Deramiocel Accepted by FDA - Marketscreener.com
0.39%
0.34%
자본화:
|
볼륨(24시간):